Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 18/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 18/20 | 0.62 |
| ▸ | ADORA2B | P29275 | 15/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.59 |
| ▸ | FBP1 | P09467 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5039892 | 0.77 | ADORA2A (0.64) | ADORA2AADORA1ADORA2BADORA3KMT2A | |
| SCHEMBL27696990 | 0.77 | ADORA2A (0.64) | ADORA2AADORA1ADORA2BADORA3KMT2A | |
| SCHEMBL27696991 | 0.77 | ADORA2A (0.64) | ADORA2AADORA1ADORA2BADORA3KMT2A | |
| SCHEMBL21877976 | 0.77 | FBP1 (0.54) | ADORA2AADORA1ADORA2BADORA3FBP1 | |
| SCHEMBL1755068 | 0.75 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL27696993 | 0.75 | ADORA2A (0.58) | ADORA2AADORA1ADORA2BADORA3KMT2A | |
| SCHEMBL982883 | 0.75 | HSPA5 (0.40) | ADORA2AADORA1ADORA2BADORA3FBP1 | |
| SCHEMBL5039628 | 0.75 | ADORA2A (0.45) | ADORA2AADORA1ADORA2BADORA3FBP1 | |
| SCHEMBL1965296 | 0.75 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL987368 | 0.74 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247294-B1 | MACROLIDES FOR TREATING DISEASES MEDIATED THROUGH PDE INHIBITION | BASILEA PHARMACEUTICA AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| EP-2049556-B1 | NEW MACROLIDES USEFUL AGAINST INFLAMMATORY AND ALLERGIC DISEASES | BASILEA PHARMACEUTICA AG (CH) | 2013-07-03 | — | — | EP | disclosed |
| US-8445451-B2 | Macrolides and uses of macrolides | BASILEA PHARMACEUTICA AG (CH) | 2013-05-21 | — | — | US | disclosed |
| US-8173609-B2 | Macrolides useful against inflammatory and allergic diseases | BASILEA PHARMACEUTICA AG (CH) | 2012-05-08 | — | — | US | disclosed |
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2011-01-27 | — | — | US | disclosed |
| EP-2247294-A2 | MACROLIDES FOR TREATING DISEASES MEDIATED THROUGH PDE INHIBITION | Basilea Pharmaceutica AG (CH) | 2010-11-10 | — | — | EP | disclosed |
| US-20100120706-A1 | Macrolides Useful Against Inflammatory and Allergic Diseases | BASILEA PHARMACEUTICA AG (CH) | 2010-05-13 | — | — | US | disclosed |
| WO-2009098320-A2 | MACROLIDES AND USES OF MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120706-A1 | Macrolides Useful Against Inflammatory and Allergic Diseases | HRH4, HRH2, IL4 | ADORA2A 1843/4885ADORA1 789/4885ADORA2B 490/4885 |
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | MRPS22, MRPS23, MRPL12 | ADORA2A 3693/4885ADORA1 2392/4885ADORA2B 2624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.